Private Equity

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

Digital infrastructure provider Lightpath partners with Oracle, leveraging AI-powered cloud tools to transform its billing and operations for the AI era.

Activist investor Shen Capital challenges Pivotree's AI strategy and leadership, rallying shareholder support for a board shake-up and a strategic review.

Montagu's carve-out of BMC Helix signals a new strategy: breaking up tech giants to unleash specialized AI power. It's a high-stakes bet on focus.

The Singapore-based ad-tech firm soars up the Fortune SEA 500 rankings, backed by staggering revenue growth, a $150M Temasek investment, and a powerful AI engine.

Csquare is going public to fund the AI boom, but its S-1 filing reveals a complex picture of soaring revenue, mounting losses, and significant debt.

A Burkinabe court nullified a key stream deal, but Franco-Nevada says Ontario law governs. The dispute is a flashpoint for geopolitical risk.

Howard Hughes Holdings' acquisition of Vantage Risk isn't just a deal; it's a bid to build a new Berkshire Hathaway, using insurance as its engine.

LPL Financial's May report reveals more than market gains; it shows a strategic pivot to advisory services that is reshaping wealth management.

Mastercard's $10,000 grants are just the headline. The real story is the ecosystem it's building to fix a broken funding model for women entrepreneurs.

The G7 unveils a plan to replace traditional aid with 'mutually beneficial partnerships.' But can this ambitious overhaul fix a broken system and tame a debt storm?

In a market of banking giants, Gulf Capital Bank makes a strategic move. By hiring a local veteran, is it signaling a resurgence of relationship-first banking?

Suntex Marinas is bundling boat insurance into its services. It’s a strategic move to deepen customer loyalty and could force the entire marine industry to adapt.

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

A new transatlantic force in financial services M&A is born as UK's Fenchurch merges with US fintech specialist Broadhaven, creating a 110-banker powerhouse.

In a tough fundraising climate where capital is scarce, Align Capital Partners just raised over $1.1B. Here's how their disciplined strategy is winning.

A private equity firm's investment in a locksmith supplier is about more than parts. It’s a bet on education, expertise, and the future of a skilled trade.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.